Search
Search filters
Type
Audience
Category
Issue
Last updated
- (-) 2019
- December 20193 results available
- November 20192 results available
- October 20192 results available
- September 20192 results available
- July 20192 results available
- June 20192 results available
- May 20193 results available
- April 20192 results available
- March 20192 results available
- January 20191 results available
Displaying 1 - 15 of 21 items.
GILENYA (fingolimod) - Risk of Congenital Malformations
AlertHealth professional risk communication | 2019-12-19
Health Canada evaluating NDMA in metformin drugs
AlertInformation update | 2019-12-05
XELJANZ / XELJANZ XR (tofacitinib) - Risk of Thrombosis
AlertHealth professional risk communication | 2019-12-02
ULORIC ® (febuxostat) - Increased Risk of Cardiovascular Fatal Outcomes
AlertHealth professional risk communication | 2019-11-04
LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions
AlertHealth professional risk communication | 2019-10-15
Avalon Fetal Monitor - Risk of Inaccurate Ultrasound-Derived Fetal Heart Rate Monitoring
AlertHealth professional risk communication | 2019-10-09
Health Canada advises Canadians to exercise caution when taking gabapentin or pregabalin with opioids
AlertInformation update | 2019-09-17
Needle-free dermal filler devices used for cosmetic skin treatments are not authorized in Canada and may pose health risks
AlertInformation update | 2019-09-13
Health Canada clarifies position on Platelet Rich Plasma treatments
AlertInformation update | 2019-07-26
Tacrolimus and the Risk of Graft Rejection due to Medication Errors: Inadvertent Switching between Different Oral Formulations
AlertHealth professional risk communication | 2019-07-22
Substance use during summer events and festivals
AlertInformation update | 2019-06-20
ALERTEC (modafinil) and the Risk of Congenital Anomalies
AlertHealth professional risk communication | 2019-06-20
Important Safety Information on Alaris Infusion Sets and Alaris 8100 Pump Module - Risk of Over-Infusion
AlertHealth professional risk communication | 2019-05-30
Health Canada suspends Allergan's licences for its Biocell breast implants after safety review concludes an increased risk of cancer
AlertInformation update | 2019-05-28